Abstract Number: L11 • ACR Convergence 2020
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for the treatment of adult patients (pts) with AS.Methods: This Phase 3, randomized, double-blind…Abstract Number: 0366 • ACR Convergence 2020
Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton associated with pain, stiffness, and disability.1 Up to 66% of patients (pts)…Abstract Number: 1226 • ACR Convergence 2020
Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK
Background/Purpose: Biosimilars have been approved for the treatment of inflammatory arthritis and evidence from randomised controlled trials have demonstrated equivalent efficacy to biologics. Etanercept biosimilar,…Abstract Number: 1338 • ACR Convergence 2020
Identification of Muscle Associated Key Genes to Support Axial Spondyloarthritis Diagnosis by Transcriptomic Approach, the MyoSpA Study
Background/Purpose: Early diagnosis of axial Spondyloarthritis (axSpA) represents a major clinical challenge nowadays. Increasing evidence has determined that early diagnosis, prompt treatment initiation and early…Abstract Number: 1849 • ACR Convergence 2020
Identification of New Associations Between Psoriatic Arthritis and the Gut Microbiota. the Mi-PART, a Phenomic Study
Background/Purpose: Perturbations of the gut microbiota have been associated with Psoriatic Arthritis (PsA), a chronic inflammatory disease. We aim to test the microbiome-metabolic interface of…Abstract Number: 1884 • ACR Convergence 2020
Disease Activity in an Axial Spondyloarthritis Cohort During the COVID-19 Pandemic
Background/Purpose: Response to the global coronavirus disease (COVID-19) pandemic has resulted in shelter-in-place orders and major changes to how people go about their daily lives.…Abstract Number: 2024 • ACR Convergence 2020
Effects of Filgotinib on Spinal Lesions in Patients with Ankylosing Spondylitis: Magnetic Resonance Imaging Data from the Placebo-Controlled, Double‑Blind, Randomized TORTUGA Trial
Background/Purpose: The oral, selective Janus kinase 1 inhibitor filgotinib (FIL) significantly improved Spondyloarthritis Research Consortium of Canada (SPARCC) MRI inflammation scores (bone marrow edema) in…Abstract Number: 0369 • ACR Convergence 2020
Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs
Background/Purpose: Pain is a debilitating symptom of ankylosing spondylitis (AS) and negatively impacts patient (pt) lives. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor engineered for…Abstract Number: 1303 • ACR Convergence 2020
Performance of Three Referral Algorithms for Diagnosing Axial Spondyloarthritis: Results from the Screening in Axial Spondyloarthritis for Psoriasis, Iritis, and Colitis Cohort
Background/Purpose: Patients presenting with back pain and psoriasis, acute anterior uveitis (AAU), or inflammatory bowel disease (IBD), represent a high-risk population for the presence of…Abstract Number: 1346 • ACR Convergence 2020
Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis
Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous. In clinical practice, both patients and…Abstract Number: 1858 • ACR Convergence 2020
Increased Proportion of TH17, TH22 and TC17 Cells and the Correlation to IL-22 and Clinical Parameters in Patients with Ankylosing Spondylitis from Northern Sweden
Background/Purpose: Increased levels of TH17 and TH22 as well as TC17 and TC22 cells have previously been associated with ankylosing spondylitis (AS). The correlation between…Abstract Number: 1885 • ACR Convergence 2020
Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) assesses axial spondyloarthritis (axSpA) with good internal consistency and discriminative capacity. However, a scientific calculator or electronic…Abstract Number: 0371 • ACR Convergence 2020
Identifying Inadequate Response Among Ankylosing Spondylitis Patients Prescribed Biologics in a Real-world Commercially Insured Adult Population in the United States
Background/Purpose: The purpose of this analysis was to assess the frequency of inadequate response (IR) over 1 year from biologic initiation among ankylosing spondylitis (AS)…Abstract Number: 1305 • ACR Convergence 2020
Is the Occurrence of Acute Anterior Uveitis Linked Primarily to Ankylosing Spondylitis (AS) or to HLA-B27? Results of a 35-Year Follow-Up Family Study of a Swiss Cohort of Patients with AS
Background/Purpose: Approximately 30% of HLA-B27(+) patients with ankylosing spondylitis (AS) have one or more episodes of acute anterior uveitis (AAU), a condition that is also…Abstract Number: 1354 • ACR Convergence 2020
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…
- 1
- 2
- 3
- …
- 41
- Next Page »